Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

<p>Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Martina S.J. McDermott (15206951) (author)
Rannpháirtithe:	Neil A. O'Brien (15206954) (author), Benjamin Hoffstrom (15206957) (author), KeWei Gong (15206960) (author), Ming Lu (15206963) (author), Jun Zhang (15206966) (author), Tong Luo (15206969) (author), Min Liang (15206972) (author), Weiping Jia (15206975) (author), Jenny J. Hong (15206978) (author), Kevin Chau (15206981) (author), Simon Davenport (15206984) (author), Bin Xie (15206987) (author), Michael F. Press (15206990) (author), Richard Panayiotou (15206993) (author), Abram Handly-Santana (15206996) (author), Joan S. Brugge (9710515) (author), Leonard Presta (15206999) (author), John Glaspy (15207002) (author), Dennis J. Slamon (15047067) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
de réir: Santiago Duro-Sánchez (14959182)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
de réir: Yuncheng Bei (16546095)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
de réir: Yuncheng Bei (16546095)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
de réir: Yuncheng Bei (16546095)
Foilsithe / Cruthaithe: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
de réir: Sheheryar Kabraji (15050565)
Foilsithe / Cruthaithe: (2025)

Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx
de réir: Yueren Fan (22687577)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
de réir: Niklas Klümper (15048887)
Foilsithe / Cruthaithe: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
de réir: Niklas Klümper (15048887)
Foilsithe / Cruthaithe: (2025)

Image 3_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.jpeg
de réir: Xi Chen (35903)
Foilsithe / Cruthaithe: (2025)

Table 2_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.docx
de réir: Xi Chen (35903)
Foilsithe / Cruthaithe: (2025)

Table 1_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.xlsx
de réir: Xi Chen (35903)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lu1cv61hk52invh2patugaq0p0